As filed with the Securities and Exchange Commission
on April 17, 2015
Registration No. 333 -_________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-3
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
________________________
China Automotive Systems, Inc.
(Exact name of Registrant as specified
in its charter)
Delaware
(State or Other Jurisdiction of
Incorporation or Organization) |
33-0885775
(I.R.S. Employer
Identification Number) |
________________________
No. 1 Henglong Road, Yu Qiao Development
Zone
Shashi District, Jing Zhou City
Hubei Province People’s Republic
of China
(86) 716- 412- 7901
(Address, including zip code, and telephone
number,
including area code, of Registrant’s
principal executive offices)
________________________
Jie Li
Chief Financial Officer
China Automotive Systems, Inc.
No. 1 Henglong Road, Yu Qiao Development
Zone
Shashi District, Jing Zhou City
Hubei Province People’s Republic
of China
(86) 27- 8757- 0027
(Name, address, including zip code, and
telephone number,
including area code, of agent for service)
________________________
Copies to:
David A. Sakowitz, Esq.
Winston & Strawn LLP
200 Park Avenue
New York, NY 10166
Tel. No.: (212) 294 6700
Fax No.: (212) 294 4700
|
Simon Luk, Esq.
Winston & Strawn
42nd Floor
Bank of China Tower
1 Garden Road
Central, Hong Kong
Tel. No.: (852) 2292 2000
Fax No.:
(852) 2292 2200 |
Approximate date of commencement of
proposed sale to the public: From time to time after the effective date of this Registration Statement.
________________
If the only securities being registered
on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or reinvestment plans, check the following box. ¨
If this form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
If this form is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If this form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in rule 12b-2
of the Exchange Act. (Check one):
Large accelerated filer ¨ |
Accelerated filer ¨ |
Non-accelerated filer ¨ |
Smaller reporting company x |
________________
CALCULATION
OF REGISTRATION FEE
Title of Each Class
of
Securities to be Registered |
Amount to be Registered
(1)(3) |
Proposed Maximum Offering Price Per Unit |
Proposed Maximum Aggregate
Offering Price (1)(4)
|
Amount of
Registration Fee (2) |
Primary Offering |
|
|
|
|
Common Stock, par value $0.0001 per share |
|
|
|
|
Preferred Stock, par value $0.0001 per share |
|
|
|
|
Debt Securities |
|
|
|
|
Warrants |
|
|
|
|
Rights |
|
|
|
|
Units |
|
|
|
|
Total Primary Offering |
|
|
$150,000,000 |
|
Secondary Offering |
|
|
|
|
Common Stock, par value $0.0001 per share |
|
|
$50,000,000 |
|
Total |
|
|
$200,000,000 |
$23,240 |
| (1) | The proposed maximum aggregate offering price for each class of securities
offered by the registrant in the primary offering will be determined from time to time by the registrant in connection with the
issuance by the registrant of the securities registered hereunder and is not specified as to each class of securities pursuant
to General Instruction II.D of Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”). |
| (2) | The proposed maximum aggregate offering price has been estimated solely for
the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. |
| (3) | Pursuant to Rule 416 under the Securities Act, this Registration Statement
also covers such additional shares as may hereafter be offered or issued to prevent dilution resulting from stock splits, stock
dividends, recapitalizations or certain other capital adjustments. |
| (4) | Pursuant to General Instruction I.B.6 of Form S-3, as long as the aggregate
market value of our common stock held by non-affiliates remains below $75 million, we will not, during any 12-month period, sell
common stock under this prospectus in a public primary offering with a value exceeding one-third of the aggregate market value
of our common stock held by non-affiliates. The aggregate market value of our outstanding common equity held by non-affiliates
on April 15, 2015 was approximately $59.27 million based on 32,121,019 shares of common stock outstanding, of which 7,999,029 shares
were held by non-affiliates, and a closing sale price on such date of $7.41 per share. As of the date hereof, we have not
offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the period of 12 calendar months that ends on and
includes the date hereof. |
The Registrant hereby amends this
Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such
date as the Commission, acting pursuant to Section 8(a), may determine.
The information in this prospectus
is not complete and may be changed. We and the selling shareholders may not sell these securities until the registration statement
relating to these securities filed with the Securities and Exchange Commission becomes effective. This prospectus is not an offer
to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not
permitted.
Subject to Completion, Dated
April 17, 2015
PROSPECTUS
$150,000,000
Common
Stock
Preferred
Stock
Debt
Securities
Warrants
Rights
Units
by
CHINA AUTOMOTIVE
SYSTEMS, INC.
and
$50,000,000
Common
Stock
by
Selling Shareholders
We may offer from time to time shares of
our common stock, preferred stock, debt securities, warrants, rights and units that include any of these securities. We will offer
securities in amounts, at prices and on terms to be determined at the time of the offering. The aggregate initial offering price
of the securities that we may offer under this prospectus will not exceed $150,000,000 (the “Company Offering”).
The selling shareholders who
are identified on page 12 of this prospectus are offering common stock (the “Shares”) for resale (by
themselves or their pledges, donees, assigns, transferees or other successors in interest) having an aggregate offering price
not to exceed $50,000,000 (the “Selling Shareholder Offering”).
This prospectus describes the general manner
in which our securities may be offered using this prospectus. Each time we offer and sell securities, we will provide you with
a prospectus supplement that will contain specific information about the terms of that offering. Any prospectus supplement
may also add, update or change information contained in this prospectus. You should carefully read this prospectus and any applicable
prospectus supplement as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before
you purchase any of the securities offered hereby.
We are registering the securities under
the Company Offering and the securities under the Selling Shareholder Offering. These securities are being registered to permit
the offering and sale of these securities from time to time in the public market or otherwise, in amounts, at prices and on terms
determined at the time of offering. We may offer the securities directly or through agents or to or through underwriters or dealers.
If any agents or underwriters are involved in the sale of the securities, their names, and any applicable purchase price, fee,
commission or discount arrangement between or among them, will be set forth, or will be calculable from the information set forth,
in an accompanying prospectus supplement. We can sell the securities through agents, underwriters or dealers only with delivery
of a prospectus supplement describing the method and terms of the offering of such securities. The
selling shareholders may sell their common stock under the Selling Shareholder Offering through ordinary brokerage transactions
or through any other means described in the section entitled “Plan of Distribution.” We will receive proceeds from
the Company Offering. However, we will not receive any proceeds from the Selling Shareholder Offering. See “Use of Proceeds.”
Our common stock is listed on the NASDAQ
Capital Market under the symbol “CAAS.” On April 15, 2015, the last reported sale price of our common stock was $7.41
per share. With respect to the Company Offering, pursuant to General Instruction I.B.6 of Form S-3, as long as the aggregate market
value of our common stock held by non-affiliates remains below $75 million, we will not, during any 12-month period, sell common
stock pursuant to the Company Offering under this prospectus in a public primary offering with a value exceeding one-third of the
aggregate market value of our common stock held by non-affiliates. The aggregate market value of our outstanding common
equity held by non-affiliates on April 15, 2015 was approximately $59.27 million based on 32,121,019 shares of common stock outstanding,
of which 7,999,029 shares were held by non-affiliates, and a closing sale price on such date of $7.41 per share. As of the
date hereof, we have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the period of 12 calendar
months that ends on and includes the date hereof.
Investing in
our securities involves a high degree of risk.
Please see “Risk Factors” beginning on page 5, and in
any applicable prospectus supplement and under similar sections in the documents we incorporate by reference into this
prospectus.
_________________________
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy
of this prospectus. Any representation to the contrary is a criminal offense.
_________________________
The date of this prospectus is April
17, 2015.
TABLE
OF CONTENTS
Prospectus
Summary |
3 |
|
|
Risk Factors |
5 |
|
|
Ratio of
Earnings to Fixed Charges |
5 |
|
|
Cautionary
Statement Regarding Forward-Looking Statements |
5 |
|
|
Use of Proceeds |
6 |
|
|
Description
of Common Stock |
6 |
|
|
Description
of Preferred Stock |
7 |
|
|
Description
of Debt Securities |
8 |
|
|
Description
of Warrants |
9 |
|
|
Description
of Rights |
11 |
|
|
Description
of Units |
12 |
|
|
Selling
Shareholders |
12 |
|
|
Plan of
Distribution |
13 |
|
|
Legal Matters |
16 |
|
|
Experts |
16 |
|
|
Where You
Can Find More Information |
16 |
|
|
Documents
Incorporated by Reference |
17 |
You should rely only on the information
incorporated by reference or provided in this prospectus, any prospectus supplement and the registration statement. We
have not authorized anyone else to provide you with different information. If anyone provides you with different or
inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any state
where the offer or sale is not permitted. You should assume that the information in this prospectus and any prospectus
supplement, or incorporated by reference, is accurate only as of the dates of those documents. Our business, financial
condition, results of operations and prospects may have changed since those dates.
ABOUT THIS PROSPECTUS
This prospectus is part of a registration
statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration, or continuous
offering, process. Under this shelf registration process, we may, from time to time, offer and sell the securities described
in this prospectus in one or more offerings up to a maximum aggregate offering price of $150,000,000. The selling shareholders
identified in this prospectus are offering common stock for resale having an aggregate offering price not to exceed $50,000,000.
This prospectus provides you with a general
description of the manner in which our securities may be offered by this prospectus. Each time we sell securities, we
will provide a prospectus supplement that will contain specific information about the terms of that offering and the offered securities. Any
prospectus supplement may also add, update or change information contained in this prospectus or in documents incorporated by reference
in this prospectus. Any prospectus supplement that contains specific information about the terms of the securities being
offered may also include a discussion of certain U.S. federal income tax consequences and any risk factors or other special considerations
applicable to those securities. Any statement that we make in this prospectus will be modified or superseded by any inconsistent
statement made by us in a prospectus supplement. The registration statement we filed with the Securities and Exchange
Commission (the “SEC”) includes exhibits that provide more detail of the matters discussed in this prospectus. You
should read this prospectus and the related exhibits filed with the SEC and any prospectus supplement, together with additional
information described under the heading “Where You Can Find More Information” before making your investment decision.
Unless otherwise indicated or the context
requires otherwise, the words “we,” “us,” “our,” the “Company” and “CAAS”
refer to China Automotive Systems, Inc. Additionally, unless we indicate otherwise, references in this prospectus to:
|
l |
“China” and the “PRC” are to the People’s Republic of China, excluding, for the purposes of this prospectus only, Taiwan and the special administrative regions of Hong Kong and Macau; |
|
|
|
|
l |
“RMB” and “Renminbi” are to the legal currency of China; and |
|
|
|
|
l |
“$,” “US$” and “U.S. dollars” are to the legal currency of the United States. |
Prospectus
Summary
This summary highlights selected information
appearing elsewhere in, or incorporated by reference in, this prospectus. While this summary highlights important information about
us, you should carefully read this prospectus (including the documents incorporated by reference into this prospectus) and the
registration statement of which this prospectus is a part in their entirety before investing in our securities, especially the
risks of investing in our securities which we discuss later in “Risk Factors.”
ABOUT CHINA AUTOMOTIVE SYSTEMS, INC.
China Automotive Systems, Inc. was incorporated
in the State of Delaware on June 29, 1999. Through its subsidiary, Great Genesis Holdings Limited (“Genesis”),
a corporation organized under the laws of the Hong Kong Special Administrative Region, China, it owns interests in nine Sino-joint
ventures and three wholly-owned subsidiaries in the People’s Republic of China which manufacture power steering systems
and/or related products for different segments of the automobile industry. Genesis also owns interests in a Brazil-based trading
company, which engages mainly in the import and sales of automotive parts in Brazil.
Henglong USA Corporation, which was incorporated
on January 8, 2007 in Troy, Michigan, is a wholly-owned subsidiary of the Company, and mainly engages in marketing of automotive
parts in North America, and provides after sales service and research and development support accordingly.
Our principal executive offices are located
at No. 1 Henglong Road, Yu Qiao Development Zone, Shashi District, Jing Zhou City, Hubei Province, People’s Republic of China.
Our telephone number is (86) 27- 8757- 0028.
SUMMARY OF THE OFFERING
This summary relates to the Company Offering
and the Selling Shareholder Offering:
Description of Securities Offered |
We may offer from time to time
shares of our common stock, preferred stock, debt securities, warrants, rights and units that include any of these securities.
We will offer securities in amounts, at prices and on terms to be determined at the time of the offering. The aggregate initial
offering price of the securities sold under this prospectus will not exceed $150,000,000 (the “Company Offering”).
The selling
shareholders who are identified on page 12 of this prospectus are offering common stock (the “Shares”)
for resale (by themselves or their pledges, donees, assigns, transferees or other successors in interest) having an
aggregate offering price not to exceed $50,000,000 (the “Selling Shareholder Offering”).
|
Common Stock Outstanding Before the Offering
|
32,121,019 shares.
|
Use of Proceeds |
We will receive proceeds from
the Company Offering. We plan to use all such proceeds for capital expenditures, possible future acquisitions, and general corporate
and working capital purposes. See “Use of Proceeds.”
We will not receive any proceeds
of the securities from the Selling Shareholder Offering.
|
Risk Factors |
The securities offered
hereby involve a high degree of risk. See “Risk Factors.” |
|
|
NASDAQ Capital Market Symbol of Common Stock |
CAAS |
Risk Factors
Any investment in our securities involves
a high degree of risk. You should carefully consider the risks factors discussed in the section entitled “Risk Factors”
contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 which are incorporated herein
by reference in their entirety, any amendment or update thereto reflected in subsequent filings with the SEC, and all other annual,
quarterly and other reports that we file with the SEC after the date of this prospectus and that also are incorporated herein by
reference, before you make a decision to invest in our company. Our business, financial conditions and results of operations could
be materially and adversely affected by many risk factors. Because of the risk factors, actual results might differ significantly
from those projected in any forward-looking statements. To the extent that any particular offering of the securities described
in this prospectus implicates additional risks, we will include a discussion of those risks in an applicable prospectus supplement.
Ratio of
Earnings to Fixed Charges
The following table sets forth our ratio
of earnings to fixed charges for the periods indicated.
| |
Fiscal Year Ended December 31, | |
| |
2014 | | |
2013 | | |
2012 | | |
2011 | | |
2010 | |
Ratio of Earnings to Fixed Charges | |
| 19.08x | | |
| 17.64x | | |
| 9.68x | | |
| 10.66x | | |
| 18.99x | |
The ratio of earnings to fixed charges
is computed by dividing (i) income before income taxes and equity in earnings of affiliated companies and fixed charges by (ii)
fixed charges. Our fixed charges consist of interest expense on indebtedness and the portion of rental expense that we deem to
be representative of the interest factor of rental payments.
Cautionary
Statement Regarding Forward-Looking Statements
This prospectus, including the sections
titled “Prospectus Summary” and “Risk Factors,” contains forward-looking statements. Forward-looking statements
convey our current expectations or forecasts of future events. All statements contained in this prospectus other than statements
of historical fact are forward-looking statements. Forward-looking statements include statements regarding our future financial
position, business strategy, budgets, projected costs, plans and objectives of management for future operations. The words “may,”
“continue,” “estimate,” “intend,” “plan,” “will,” “believe,”
“project,” “expect,” “could,” “would,” “anticipate” and similar expressions
may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking.
You should not rely on forward-looking
statements as predictions of future events or results. Any or all of our forward-looking statements in this prospectus may turn
out to be inaccurate. We have based these forward-looking statements largely on our current expectations and projections about
future events and financial trends that we believe may affect our financial condition, results of operations, business strategy
and financial needs. They may be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties,
including the risks, uncertainties and assumptions described in “Risk Factors.” In light of these risks, uncertainties
and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur as contemplated, and actual
results could differ materially from those anticipated or implied by the forward-looking statements.
These forward-looking statements speak
only as of the date of this prospectus. In evaluating these statements, you should consider various factors, including the risks
described in or incorporated by reference into this prospectus under “Risk Factors” and elsewhere. These factors may
cause our actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to
time and it is not possible for us to predict all factors that may cause actual results to differ materially from those contained
in any forward-looking statements. Unless required by law, we undertake no obligation to publicly update or revise any forward-looking
statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe
in the reports we will file from time to time with the SEC after the date of this prospectus. See “Where You Can Find More
Information.”
As described in “Documents Incorporated
by Reference” below, certain documents filed by us in the future with the SEC are automatically deemed to be incorporated
by reference into this prospectus. Such documents may include forward-looking statements. To the extent they do, the previous three
paragraphs apply to such forward-looking statements as well, except that such other documents’ forward-looking statements
shall be deemed to speak only as of the filing date of the applicable other document.
Use of Proceeds
With respect to the Company Offering, we
will retain broad discretion over the use of net proceeds to us from the sale of our securities offered hereby. Unless
we state otherwise in any accompanying prospectus supplement, we intend to use the net proceeds from the sale of the securities
offered pursuant to the Company Offering by this prospectus for capital expenditures, possible future acquisitions, and general
corporate and working capital purposes.
We will not receive any proceeds of the
sale of common stock from the Selling Shareholder Offering.
Description
of Common Stock
We are authorized to issue 80,000,000 shares
of common stock of $0.0001 par value per share. As of March 31, 2015, there were 32,121,019 shares of our common stock issued
and outstanding.
General
The holders of common stock are entitled
to one vote per share on all matters submitted to a vote of stockholders, including the election of directors. There is no right
to cumulate votes in the election of directors. The holders of common stock are entitled to any dividends that may be declared
by the board of directors out of funds legally available therefore subject to the prior rights of holders of preferred stock and
any contractual restrictions we have against the payment of dividends on common stock. In the event of our liquidation or dissolution,
holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation
preferences of any outstanding shares of preferred stock (if any). Holders of common stock have no preemptive rights and have
no right to convert their common stock into any other securities. All of the outstanding shares of common stock are fully
paid and non-assessable.
Dividends
On May 27, 2014, the Company announced
the payment of a special cash dividend of $0.18 per common share to the Company’s shareholders of record as of the close
of business on June 26, 2014. The Company does not anticipate paying any other cash dividends in the foreseeable future. The Company
currently intends to retain future earnings, if any, to finance operations and the expansion of its business. Any future determination
to pay cash dividends will be at the discretion of the Company’s board of directors and will be based upon the Company’s
financial condition, operating results, capital requirements, plans for expansion, restrictions imposed by any financing arrangements
and any other factors that the Company’s board of directors deems relevant.
Transfer Agent
The transfer agent and registrar for our
common stock is Securities Transfer Corporation.
Listing
Our common stock is listed on the NASDAQ
Capital Market under the symbol “CAAS.”
Delaware Anti-Takeover Law
We are subject to the provisions of Section
203 of the Delaware General Corporation Law. In general, this section prohibits a publicly held Delaware corporation
from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction
in which the person becomes an interested stockholder, unless:
| · | before the date on which the stockholder became an interested stockholder, the corporation’s
board of directors approved either the business combination or the transaction in which the person became an interested stockholder; |
| · | the stockholder acquires more than 85% of the outstanding voting stock of the corporation, excluding
shares held by directors who are officers or held in certain employee stock plans, upon consummation of the transaction in which
the stockholder becomes an interested stockholder; or |
| · | the business combination is approved by the board of directors and by two-thirds of the outstanding
voting stock of the corporation that is not held by the interested stockholder, at a meeting of the stockholders held on or after
the date of the business combination. |
Section 203 defines “business combination”
to include:
| · | any merger or consolidation involving the corporation and the interested stockholder; |
| · | any sale, transfer, pledge or other disposition of 10% or more of our assets involving the interested
stockholder; |
| · | in general, any transaction that results in the issuance or transfer by us of any of our stock
to the interested stockholder; or |
| · | the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges
or other financial benefits provided by or through the corporation. |
Indemnification of Directors and Officers
Section 145 of the Delaware General Corporation
Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms
sufficiently broad to permit such indemnification under certain circumstances for liabilities (including reimbursement for expenses
incurred) arising under the Securities Act of 1933, as amended (the “Securities Act”). There are no specific
provisions relating to indemnification of directors and officers in our certificate of incorporation or bylaws.
Description
of Preferred Stock
We are authorized to issue 20,000,000 shares
of preferred stock of $0.0001 par value per share. As of March 31, 2015, there were no shares of our preferred stock issued
or outstanding. We may amend from time to time our certificate of incorporation to increase the number of authorized shares of
preferred stock. Any such amendment would require the approval of the holders of a majority of our shares entitled to vote.
General
The particular terms of any series of preferred
stock that we offer under this prospectus will be described in the applicable prospectus supplement relating to that series of
preferred stock. Those terms may include:
| • | the title and liquidation preference per share of the preferred stock and the number of shares
offered; |
| • | the purchase price of the preferred stock; |
| • | the dividend rate (or method of calculation), the dates on which dividends will be payable, whether
dividends shall be cumulative and, if so, the date from which dividends will begin to accumulate; |
| • | any redemption or sinking fund provisions of the preferred stock; |
| • | any conversion, redemption or exchange provisions of the preferred stock; |
| • | the voting rights, if any, of the preferred stock; and |
| • | any additional dividend, liquidation, redemption, sinking fund and other rights, preferences, privileges,
limitations and restrictions of the preferred stock. |
You should refer to the certificate of
designations establishing a particular series of preferred stock which will be filed with the Secretary of State of the State of
Delaware and the SEC in connection with any offering of preferred stock.
Each prospectus supplement relating to
a series of preferred stock may describe certain U.S. federal income tax considerations applicable to the purchase, holding and
disposition of such series of preferred stock.
Dividends
The preferred stock will be preferred over
the common stock as to payment of dividends. Before any dividends or distributions (other than dividends or distributions payable
in common stock or other stock ranking junior to that series of preferred stock as to dividends and upon liquidation) on the common
stock or other stock ranking junior to that series of preferred stock as to dividends and upon liquidation shall be declared and
set apart for payment or paid, the holders of shares of each series of preferred stock (unless otherwise set forth in the applicable
prospectus supplement) will be entitled to receive dividends when, as and if declared by our board of directors or, if dividends
are cumulative, full cumulative dividends for the current and all prior dividend periods. The Company has never paid preferred
stock or common stock cash dividends. We currently intend to retain earnings, if any, to fund the development and growth of our
business. Our payment of any future dividends will be at the discretion of our board of directors after taking into account various
factors, including our financial condition, operating results, cash needs and growth plans.
Description
of Debt Securities
We may issue debt securities, in one or
more series, as either senior or subordinated debt or as senior or subordinated convertible debt. When we offer to sell debt securities,
we will describe the specific terms of any debt securities offered from time to time in a supplement to this prospectus, which
may supplement or change the terms outlined below. Senior debt securities will be issued under one or more senior indentures, dated
as of a date prior to such issuance, between us and a trustee to be named in a prospectus supplement, as amended or supplemented
from time to time. Any subordinated debt securities will be issued under one or more subordinated indentures, dated as of a date
prior to such issuance, between us and a trustee to be named in a prospectus supplement, as amended or supplemented from time to
time. The indentures will be subject to and governed by the Trust Indenture Act of 1939, as amended.
Before we issue any debt securities, the
form of indentures will be filed with the SEC and incorporated by reference as an exhibit to the registration statement of which
this prospectus is a part or as an exhibit to a current report on Form 8-K. For the complete terms of the debt securities, you
should refer to the applicable prospectus supplement and the form of indentures for those particular debt securities. We encourage
you to read the applicable prospectus supplement and the form of indenture for those particular debt securities before you purchase
any of our debt securities.
General
We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:
| • | whether or not such debt securities are guaranteed; |
| • | the principal amount being offered, and if a series, the total amount authorized and the total
amount outstanding; |
| • | any limit on the amount that may be issued; |
| • | whether or not we will issue the series of debt securities in global form, the terms and who the
depositary will be; |
| • | the annual interest rate, which may be fixed or variable, or the method for determining the rate
and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment
dates or the method for determining such dates; |
| • | whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
| • | the terms of the subordination of any series of subordinated debt; |
| • | the place where payments will be payable; |
| • | restrictions on transfer, sale or other assignment, if any; |
| • | our right, if any, to defer payment of interest and the maximum length of any such deferral period; |
| • | the date, if any, after which, and the price at which, we may, at our option, redeem the series
of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; |
| • | the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt
securities and the currency or currency unit in which the debt securities are payable; |
| • | any restrictions our ability and/or the ability of our subsidiaries to: |
| • | incur additional indebtedness; |
| • | issue additional securities; |
| • | pay dividends and make distributions in respect of our capital stock and the capital stock of our
subsidiaries; |
| • | place restrictions on our subsidiaries’ ability to pay dividends, make distributions or transfer
assets; |
| • | make investments or other restricted payments; |
| • | sell or otherwise dispose of assets; |
| • | enter into sale-leaseback transactions; |
| • | engage in transactions with stockholders and affiliates; |
| • | issue or sell stock of our subsidiaries; or |
| • | effect a consolidation or merger; |
| • | whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based,
asset-based or other financial ratios; |
| • | a discussion of any material United States federal income tax considerations applicable to the
debt securities; |
| • | information describing any book-entry features; |
| • | provisions for a sinking fund purchase or other analogous fund, if any; |
| • | the denominations in which we will issue the series of debt securities; |
| • | the currency of payment of debt securities if other than U.S. dollars and the manner of determining
the equivalent amount in U.S. dollars; and |
| • | any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities,
including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be
required by us or advisable under applicable laws or regulations. |
Conversion or Exchange Rights
We will set forth in the prospectus supplement
the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities.
We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We
may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the
series of debt securities receive would be subject to adjustment.
Description
of Warrants
We may issue warrants for the purchase
of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together
with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.
While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms
of any series of warrants in more detail in the applicable prospectus supplement. The terms of any warrants offered under a prospectus
supplement may differ from the terms described below.
We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we
are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants
and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement
and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to
read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus,
as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the
terms of the warrants.
General
We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including:
| • | the offering price and aggregate number of warrants offered; |
| • | the currency for which the warrants may be purchased; |
| • | if applicable, the designation and terms of the securities with which the warrants are issued and
the number of warrants issued with each such security or each principal amount of such security; |
| • | if applicable, the date on and after which the warrants and the related securities will be separately
transferable; |
| • | in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable
upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased
upon such exercise; |
| • | in the case of warrants to purchase common stock or preferred stock, the number of shares of common
stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares
may be purchased upon such exercise; |
| • | the effect of any merger, consolidation, sale or other disposition of our business on the warrant
agreements and the warrants; |
| • | the terms of any rights to redeem or call the warrants; |
| • | any provisions for changes to or adjustments in the exercise price or number of securities issuable
upon exercise of the warrants; |
| • | the dates on which the right to exercise the warrants will commence and expire; |
| • | the manner in which the warrant agreements and warrants may be modified; |
| • | a discussion of any material or special United States federal income tax consequences of holding
or exercising the warrants; |
| • | the terms of the securities issuable upon exercise of the warrants; and |
| • | any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders
of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:
| • | in the case of warrants to purchase debt securities, the right to receive payments of principal
of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable
indenture; or |
| • | in the case of warrants to purchase common stock or preferred stock, the right to receive dividends,
if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. |
Exercise of Warrants
Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. Holders of the warrants may exercise the warrants at any time up to the specified time on the expiration
date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void.
Holders of the warrants may exercise the
warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and
paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that
the holder of the warrant will be required to deliver to the warrant agent.
If fewer than all of the warrants represented
by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If
we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the
exercise price for warrants.
Description
of Rights
We may issue rights to purchase our common
stock, preferred stock or debt securities, in one or more series. Rights may be issued independently or together with any other
offered security and may or may not be transferable by the person purchasing or receiving the subscription rights. In connection
with any rights offering to our stockholders, we may enter into a standby underwriting arrangement with one or more underwriters
pursuant to which such underwriters will purchase any offered securities remaining unsubscribed after such rights offering. In
connection with a rights offering to our stockholders, we will distribute certificates evidencing the rights and a prospectus supplement
to our stockholders on the record date that we set for receiving rights in such rights offering. The applicable prospectus supplement
or free writing prospectus will describe the following terms of rights in respect of which this prospectus is being delivered:
| • | the title of such rights; |
| • | the securities for which such rights are exercisable; |
| • | the exercise price for such rights; |
| • | the date of determining the security holders entitled to the rights distribution; |
| • | the number of such rights issued to each security holder; |
| • | the extent to which such rights are transferable; |
| • | if applicable, a discussion of the material United States federal income tax considerations applicable
to the issuance or exercise of such rights; |
| • | the date on which the right to exercise such rights shall commence, and the date on which such
rights shall expire (subject to any extension); |
| • | the conditions to completion of the rights offering; |
| • | any provisions for changes to or adjustments in the exercise price or number of securities issuable
upon exercise of the rights; |
| • | the extent to which such rights include an over-subscription privilege with respect to unsubscribed
securities; |
| • | if applicable, the material terms of any standby underwriting or other purchase arrangement that
we may enter into in connection with the rights offering; and |
| • | any other terms of such rights, including terms, procedures and limitations relating to the exchange
and exercise of such rights. |
Each right will entitle the holder thereof
the right to purchase for cash such amount of common stock, preferred stock or debt securities, or any combination thereof, at
such exercise price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating
to the rights offered thereby. Rights may be exercised at any time up to the close of business on the expiration date for such
rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised rights will
become void. Rights may be exercised as set forth in the prospectus supplement relating to the rights offered thereby. Upon receipt
of payment and the proper completion and due execution of the rights certificate at the office of the rights agent, if any, or
any other office indicated in the prospectus supplement, we will forward, as soon as practicable, the shares of common stock and/or
preferred stock and/or the debt securities purchasable upon such exercise. We may determine to offer any unsubscribed offered securities
directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods,
including pursuant to standby underwriting arrangements, as set forth in the applicable prospectus supplement.
Description
of Units
As specified in the applicable prospectus
supplement, we may issue, in one more series, units consisting of common stock, preferred stock, debt securities and/or warrants
or rights for the purchase of common stock, preferred stock and/or the debt securities in any combination. The applicable prospectus
supplement will describe:
| • | the securities comprising the units, including whether and under what circumstances the securities
comprising the units may be separately traded; |
| • | the terms and conditions applicable to the units, including a description of the terms of any applicable
unit agreement governing the units; and |
| • | a description of the provisions for the payment, settlement, transfer or exchange of the units. |
Selling
Shareholders
The Shares being offered for resale by
the selling shareholders are issued and outstanding and are beneficially owned by the selling shareholders.
The table below lists the selling shareholders
and other information regarding the beneficial ownership of shares of common stock by each selling shareholder as of March 31,
2015, and the Shares being offered by this prospectus by each selling shareholder.
The selling shareholders may sell all,
some or none of their Shares in the Selling Shareholder Offering. See “Plan of Distribution.”
Name of Selling Shareholder | |
Number of Shares of Common Stock Beneficially Owned Prior to Offering | | |
Percentage of Class | | |
Maximum Number of Shares to be Sold Pursuant to The Prospectus | | |
Number of Shares of Common Stock Beneficially Owned After Offering (6) | | |
Percentage of Class (6) | |
Hanlin Chen (1) | |
| 17,849,014 (4) | | |
| 55.57 | % | |
| 5,000,000 (5) | | |
| 12,849,014 | | |
| 40.00 | % |
Li Ping Xie (2) | |
| 17,849,014 (4) | | |
| 55.57 | % | |
| 5,000,000 (5) | | |
| 12,849,014 | | |
| 40.00 | % |
Wiselink Holdings Limited (3) | |
| 3,023,542 | | |
| 9.41 | % | |
| 1,000,000 | | |
| 2,023,542 | | |
| 6.30 | % |
| (1) | Mr. Hanlin Chen is the Chairman and a Director of the Company. |
| (2) | Ms. Li Ping Xie is the wife of Mr. Hanlin Chen. |
| (3) | Wiselink Holdings Limited is a company controlled by Mr. Hanlin Chen. |
| (4) | Includes 13,322,547 shares directly owned by Mr. Hanlin Chen; 1,502,925 shares directly owned by Ms. Li Ping Xie; and 3,023,542
shares directly owned by Wiselink Holdings Limited. |
| (5) | Includes 3,000,000 Shares directly owned by Mr. Hanlin Chen; 1,000,000 Shares directly owned by Ms. Li Ping Xie; and 1,000,000
Shares directly owned by Wiselink Holdings Limited. |
| (6) | Assuming that the selling shareholders sell the maximum number of Shares pursuant to this prospectus. |
Plan of
Distribution
The Company Offering
Pursuant to General Instruction I.B.6.
of Form S-3, under the Company Offering, we are permitted to utilize the registration statement of which this prospectus forms
a part to sell a maximum amount of common stock equal to one-third of the aggregate market value of the outstanding voting and
non-voting common equity held by our non-affiliates in any 12-month period. We may, from time to time, offer the common
stock registered hereby up to this maximum amount.
We may sell the securities offered through
this prospectus (i) to or through underwriters or dealers, (ii) directly to purchasers, including our affiliates, (iii) through
agents, (iv) in “at the market offerings,” within the meaning of Rule 415(a)(4) under the Securities Act, to or through
a market maker or into an existing trading market, on an exchange or otherwise, or (v) through a combination of any these
methods. The securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing at the time
of sale, prices related to the prevailing market prices, or negotiated prices. The prospectus supplement will include the following
information:
| · | the terms of the offering; |
| · | the names of any underwriters or agents; |
| · | the name or names of any managing underwriter or underwriters; |
| · | the purchase price of the securities; |
| · | any over-allotment options under which underwriters may purchase additional securities from us; |
| · | the net proceeds from the sale of the securities; |
| · | any delayed delivery arrangements; |
| · | any underwriting discounts, commissions and other items constituting underwriters’ compensation; |
| · | any discounts or concessions allowed or reallowed or paid to dealers; |
| · | any commissions paid to agents; and |
| · | any securities exchange or market on which the securities may be listed. |
Sale Through Underwriters or Dealers
Only underwriters named in any prospectus
supplement are underwriters of the securities offered by such prospectus supplement.
If underwriters are used in the sale, the
underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase
agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated
transactions. Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described
in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities
to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more
firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase
the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all the offered securities
if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts
or concessions allowed or reallowed or paid to dealers.
In compliance with FINRA guidelines, the
aggregate maximum fees or other items of value to be received by any FINRA member or independent broker-dealer will not exceed
8% of the gross proceeds of any offering pursuant to this prospectus and any applicable prospectus supplement or pricing supplement,
as the case may be.
If dealers are used in the sale of securities
offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities to the
public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the
dealers and the terms of the transaction.
Direct Sales and Sales Through Agents
We may sell the securities offered through
this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold through agents
designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities
and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will
agree to use its reasonable best efforts to solicit purchases for the period of its appointment.
We may sell the securities directly to
institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to
any sale of those securities. The terms of any such sales will be described in the prospectus supplement.
Delayed Delivery Contracts
If the prospectus supplement indicates,
we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at
the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified
date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable
prospectus supplement will describe the commission payable for solicitation of those contracts.
Market Making, Stabilization and
Other Transactions
Unless the applicable prospectus supplement
states otherwise, other than our common stock, all securities we offer under this prospectus will be a new issue and will have
no established trading market. We may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters
that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any
time without notice. Therefore, we cannot assure you that the securities will have a liquid trading market.
Any underwriter may also engage in stabilizing
transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Exchange Act. Stabilizing
transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or maintaining
the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution
has been completed in order to cover syndicate short positions.
In connection with an offering, an underwriter
may purchase and sell securities in the open market. These transactions may include short sales, stabilizing transactions and purchases
to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of securities than
they are required to purchase in the offering. “Covered” short sales are sales made in an amount not greater than the
underwriters’ option to purchase additional securities, if any, from us in the offering. If the underwriters have an over-allotment
option to purchase additional securities from us, the underwriters may close out any covered short position by either exercising
their over-allotment option or purchasing securities in the open market. In determining the source of securities to close out the
covered short position, the underwriters may consider, among other things, the price of securities available for purchase in the
open market as compared to the price at which they may purchase securities through the over-allotment option. “Naked”
short sales are any sales in excess of such option or where the underwriters do not have an over-allotment option. The underwriters
must close out any naked short position by purchasing securities in the open market. A naked short position is more likely to be
created if the underwriters are concerned that there may be downward pressure on the price of the securities in the open market
after pricing that could adversely affect investors who purchase in the offering.
Penalty bids permit the underwriters to
reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased
in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions
and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters
may, if they commence these transactions, discontinue them at any time.
Derivative Transactions and Hedging
We
and the underwriters may engage in derivative transactions involving the securities. These derivatives may consist of short sale
transactions and other hedging activities. The underwriters may acquire a long or short position in the securities, hold or resell
securities acquired and purchase options or futures on the securities and other derivative instruments with returns linked to or
related to changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security
lending or repurchase agreements with the underwriters. The underwriters may effect the derivative transactions through sales of
the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions
by others. The underwriters may also use the securities purchased or borrowed from us or others (or, in the case of derivatives,
securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close
out any related open borrowings of the securities.
Loans of Securities
We
may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus
and an applicable prospectus supplement.
General Information
Agents, underwriters, and dealers may be
entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under
the Securities Act. Our agents, underwriters, and dealers, or their affiliates, may be customers of, engage in transactions with
or perform services for us, in the ordinary course of business.
The Selling Shareholder Offering
We are registering the Shares which are
issued and outstanding and are beneficially held by the selling shareholders identified in this prospectus for offer to resale.
We will not receive any of the proceeds from such resale by the selling shareholders. We will bear all fees and expenses incident
to our obligation to register the Shares under the Selling Shareholder Offering.
The selling shareholders may sell all or
a portion of the Shares beneficially owned by them and offered hereby from time to time directly or through one or more underwriters,
broker-dealers or agents. If the Shares are sold through underwriters or broker-dealers, the selling shareholders will be responsible
for underwriting discounts or commissions or agent’s commissions. The Shares may be sold in one or more transactions at fixed
prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated
prices. These sales may be effected in transactions, which may involve crosses or block transactions,
| · | on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale; |
| · | in the over-the-counter market; |
| · | in transactions otherwise than on these exchanges or systems or in the over-the-counter market; |
| · | through the writing of options, whether such options are listed on an options exchange or otherwise; |
| · | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| · | block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the
block as principal to facilitate the transaction; |
| · | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
| · | an exchange distribution in accordance with the rules of the applicable exchange; |
| · | privately negotiated transactions; |
| · | broker-dealers may agree with the selling shareholders to sell a specified number of such shares or other security at a stipulated
price per share or per unit; |
| · | a combination of any such methods of sale; and |
| · | any other method permitted pursuant to applicable law. |
If the selling shareholders effect such
transactions by selling the Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
may receive commissions in the form of discounts, concessions or commissions from the selling shareholders or commissions from
purchasers of the Shares for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or
commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the Shares or otherwise, the selling shareholders may enter into hedging transactions with
broker-dealers, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The selling
shareholders may also sell the Shares short and deliver Shares covered by this prospectus to close out short positions and to return
borrowed shares in connection with such short sales. The selling shareholders may also loan or pledge Shares to broker-dealers
that in turn may sell such shares.
The selling shareholders may pledge or
grant a security interest in some or all of the Shares owned by them and, if they default in the performance of their secured obligations,
the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant to this prospectus or
any supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending,
if necessary, the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders
under this prospectus. The selling shareholders also may transfer and donate shares of common stock in other circumstances in which
case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.
The selling shareholders and any broker-dealer
participating in the distribution of the securities may be deemed to be “underwriters” within the meaning of the Securities
Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting
commissions or discounts under the Securities Act. At the time a particular offering of the Shares is made, a prospectus supplement,
if required, will be distributed to set forth the aggregate amount of Shares being offered and the terms of the offering, including
the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the
selling shareholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.
Under the securities laws of some states,
shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some
states shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an
exemption from registration or qualification is available and is complied with.
There can be no assurance that any selling
shareholders will sell any or all of the Shares registered pursuant to the registration statement of which this prospectus forms
a part.
The selling shareholders and any other
person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), and the rules and regulations thereunder, including, without limitation, Regulation M
of the Exchange Act, which may limit the timing of purchases and sales of any of the Shares by the selling shareholders and any
other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of Shares to engage
in market-making activities with respect to shares. All of the foregoing may affect the marketability of the Shares and the ability
of any person or entity to engage in market-making activities with respect to the shares.
We will pay all expenses of the registration
of the Shares, estimated to be $65,240 in total, including, without limitation, SEC filing fees and expenses of compliance with
state securities or “blue sky” laws; provided, however, that the selling shareholders will pay all underwriting
discounts and selling commissions, if any, in connection with any underwritten offering of Shares by the selling shareholders.
We may be indemnified by the selling shareholders against civil liabilities, including liabilities under the Securities Act, that
may arise from any written information furnished to us by the selling shareholders specifically for use in this prospectus, or
we may be entitled to contribution.
Once sold under the registration statement,
of which this prospectus forms a part, the Shares will be freely tradable in the hands of persons other than our affiliates.
Legal Matters
The validity of the securities offered
by this prospectus will be passed upon for us by Winston & Strawn LLP, New York, New York.
Experts
The financial statements and management’s
assessment of the effectiveness of internal control over financial reporting (which is included in Management’s Report on
Internal Control Over Financial Reporting) incorporated in this Prospectus by reference to our Annual Report on Form 10-K for the
year ended December 31, 2014 have been so incorporated in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
Where You
Can Find More Information
We have filed with the SEC a registration
statement on Form S-3 under the Securities Act with respect to the securities offered hereby. We also file periodic and current
reports pursuant to the Exchange Act, proxy statements and other information with the SEC. This prospectus, which constitutes a
part of the registration statement, does not contain all of the information in the registration statement and the exhibits of the
registration statement. For further information with respect to us and the shares being offered under this prospectus, we refer
you to the registration statement, including the exhibits and schedules thereto, and the documents incorporated by reference in
this prospectus and the registration statement.
You may read and copy the registration
statement of which this prospectus is a part at the SEC’s Public Reference Room, which is located at 100 F Street N.E., Washington,
D.C. 20549. You can request copies of the registration statement by writing to the SEC and paying a fee for the copying cost. Please
call the SEC at 1-800-SEC-0330 for more information about the operation of the SEC’s Public Reference Room. In addition,
the SEC maintains an Internet web site, which is located at www.sec.gov, which contains
reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may
access the registration statement of which this prospectus is a part, as well as our periodic and current reports filed pursuant
to the Exchange Act, proxy statements and other information, at the SEC’s Internet web site.
We maintain an Internet web site at www.caasauto.com.
We have not incorporated by reference into this prospectus the information on our web site, and you should not consider
it to be a part of this prospectus.
Documents
Incorporated by Reference
The following documents filed by us with
the SEC are incorporated into this prospectus by reference:
| · | our Annual Report on Form 10-K for the fiscal year ended December 31, 2014; |
| · | our proxy statement filed pursuant to Section 14(a) of the Exchange Act for the annual meeting
of stockholders for the year 2014; and |
| · | the description of the our common stock contained in the Registration Statement on Form 10-SB filed
by our predecessor, Visions-In-Glass, Inc., with the SEC under Section 12 of the Exchange Act on August 27, 2001, including any
amendments or reports filed for the purpose of updating such description. |
All documents subsequently filed by us
with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act and before the termination of this offering shall
be deemed to be incorporated by reference into this prospectus. Any statement contained in a document incorporated or deemed to
be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent
that a statement contained herein, or in any other subsequently filed document that also is or is deemed to be incorporated by
reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this prospectus. Notwithstanding the foregoing, information furnished under
Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference
in this prospectus.
We will provide, without charge, to each
person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon the written or oral request of such
person, a copy of all or any of the documents that have been incorporated herein by reference, but are not delivered with this
prospectus, other than exhibits to such documents (unless such exhibits are specifically incorporated by reference herein). Requests
for such copies should be directed to:
China Automotive Systems, Inc.
No. 1 Henglong Road, Yu Qiao Development Zone
Shashi District, Jing Zhou City
Hubei Province
People’s Republic of China
Attn: Jie Li
* * *
You may rely on the information contained
in this prospectus. We have not authorized anyone to provide information different from that contained in this prospectus. Neither
the delivery of this prospectus nor the sale of securities means that information contained in this prospectus is correct after
the date of this prospectus. This prospectus is not an offer to sell or a solicitation of an offer to buy securities in any circumstances
under which the offer or solicitation is unlawful.
Part II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance
and Distribution
The following table sets forth the costs
and expenses, other than underwriting discounts and commissions, to be paid by the Registrant in connection with the issuance and
distribution of the securities being registered. All amounts other than the SEC registration fee are estimates.
| |
Amount to be paid | |
SEC registration fee | |
$ | 23,240 | |
Legal fees and expenses | |
$ | 20,000 | |
Accounting fees and expenses | |
$ | 15,000 | |
Printing and engraving expenses | |
$ | 5,000 | |
Miscellaneous | |
$ | 2,000 | |
Total | |
$ | 65,240 | |
Item 15. Indemnification of Directors
and Officers
Section 145 of the Delaware General Corporation
Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms
sufficiently broad to permit such indemnification under certain circumstances for liabilities (including reimbursement for expenses
incurred) arising under the Securities Act. There are no specific provisions relating to indemnification of directors and officers
in our certificate of incorporation or bylaws.
Item 16. Exhibits
Exhibit |
Description |
|
|
1.1* |
Form of Underwriting Agreement. |
|
|
4.1 |
Certificate of Incorporation of Visions-In-Glass, Inc., now known as China Automotive Systems, Inc. (Incorporated by reference to Exhibit 3(i) to the Registration Statement on Form 10-SB filed by us with the Commission on August 27, 2001). |
|
|
4.1.1 |
Certificate of Amendment to Certificate of Incorporation, filed May 19, 2003 (Incorporated by reference to Exhibit 4.1.1 to the Registration Statement on Form S-3 (file no. 333-133331) filed by us with the Commission on April 17, 2006). |
|
|
4.1.2 |
Specimen Stock Certificate for Common Stock (filed herewith). |
|
|
4.2 |
Bylaws (Incorporated by reference to Exhibit 3(ii) to the Registration Statement on Form 10-SB filed by us with the Commission on August 27, 2001). |
|
|
4.3* |
Form of Stock Certificate for Preferred Stock. |
|
|
4.4* |
Form of Indenture, including form of Note. |
|
|
4.5* |
Form of Warrant Agreement, including form of Warrant. |
|
|
4.6* |
Form of Rights Certificate. |
|
|
4.7* |
Form of Pledge Agreement. |
|
|
4.8* |
Form of Unit Agreement. |
|
|
5.1 |
Opinion of Winston & Strawn LLP (filed herewith). |
|
|
12.1 |
Computation of Ratio of Earnings to Fixed Charges (filed herewith). |
|
|
23.1 |
Consent of Independent Registered Public Accounting Firm (filed herewith). |
|
|
23.2 |
Consent of Winston & Strawn LLP (included in Exhibit 5.1). |
|
|
24.1 |
Power of Attorney (included on Signature Page). |
|
|
25.1** |
Form T-1, Statement of Eligibility and Qualification under the Trust Indenture Act of 1939 of the Trustee under any indenture constituting Exhibit 4.4 hereto. |
| * | To be filed, if applicable, by amendment or as an exhibit to a document to be incorporated by reference
herein in connection with an offering of securities. |
| ** | To be filed separately under the electronic form type
305B2, if applicable. |
Item 17. Undertakings
The undersigned registrant hereby undertakes:
| (1) | To file, during any period in which offers or sales are being made pursuant to this Registration
Statement, a post-effective amendment to this Registration Statement: |
| (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum
aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
and |
| (iii) | to include any material information with respect to the plan of distribution not previously disclosed
in this Registration Statement or any material change to such information in this Registration Statement; |
provided, however, that subparagraphs
(i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by these subparagraphs
is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section
15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement, or is contained
in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement;
| (2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such
post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; |
| (3) | To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering; |
| (4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
| (A) | Each prospectus filed by the registrant pursuant to Rule 424(b)(3)shall be deemed to be part of
the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
| (B) | Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a
registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the
purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in the registration statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement
that was made in the registration statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such effective date; |
| (5) | That, for the purpose of determining liability of the registrant under the Securities Act of 1933
to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser: |
| (i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering
required to be filed pursuant to Rule 424; |
| (ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant; |
| (iii) | The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
| (iv) | Any other communication that is an offer in the offering made by the undersigned registrant to
the purchaser; |
| (6) | That for purposes of determining any liability under the Securities Act of 1933, each filing of
the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that
is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; |
| (7) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to directors, officers and controlling persons of the registrant pursuant to any charter provision, by law or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue;
and |
| (8) | The undersigned registrant hereby undertakes to file an application for the purpose of determining
the eligibility of the trustee to act under subsection (a) of section 310 of the Trust Indenture Act (“Act”) in accordance
with the rules and regulations prescribed by the Commission under section 305(b)(2) of the Act. |
Signatures
Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in Hubei, People’s Republic of China, on April 17, 2015.
|
CHINA AUTOMOTIVE SYSTEMS, INC. |
|
|
|
|
|
|
|
By: |
/s/ Hanlin Chen |
|
Hanlin Chen |
|
Chairman |
Power of
Attorney
We, the undersigned directors and/or officers
of China Automotive Systems, Inc. (the “Registrant”), hereby severally constitute and appoint Hanlin Chen and Jie Li,
and each of them individually, with full powers of substitution and resubstitution, our true and lawful attorneys, with full powers
to them and each of them to sign for us, in our names and in the capacities indicated below, the Registration Statement on this
Form S-3 filed with the Securities and Exchange Commission, and any and all amendments to said Registration Statement (including
post-effective amendments), and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933 in connection
with the registration under the Securities Act of 1933 of the Registrant’s equity securities, and to file or cause to be
filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person,
and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or
cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated
below.
Dated: April 17, 2015 |
|
/s/ Hanlin Chen |
|
|
Name: |
Hanlin Chen |
|
|
Title: |
Chairman and Director |
|
|
|
|
|
Dated: April 17, 2015 |
|
/s/ Qizhou Wu |
|
|
Name: |
Qizhou Wu |
|
|
Title: |
Chief Executive Officer, President and Director |
|
|
|
|
|
Dated:April 17, 2015 |
|
/s/ Jie Li |
|
|
Name: |
Jie Li |
|
|
Title: |
Chief Financial Officer |
|
|
|
|
|
Dated:April 17, 2015 |
|
/s/ Daming Hu |
|
|
Name: |
Daming Hu |
|
|
Title: |
Chief Accounting Officer |
|
|
|
|
|
Dated:April 17, 2015 |
|
/s/ Robert Tung |
|
|
Name: |
Robert Tung |
|
|
Title: |
Director |
|
|
|
|
|
Dated: April 17, 2015 |
|
/s/ Guangxun Xu |
|
|
Name: |
Guangxun Xu |
|
|
Title: |
Director |
|
|
|
|
|
Dated: April 17, 2015 |
|
/s/ Arthur Wong |
|
|
Name: |
Arthur Wong |
|
|
Title: |
Director |
|
Exhibit Index
Exhibit |
Description |
|
|
1.1* |
Form of Underwriting Agreement. |
|
|
4.1 |
Certificate of Incorporation of Visions-In-Glass, Inc., now known as China Automotive Systems, Inc. (Incorporated by reference to Exhibit 3(i) to the Registration Statement on Form 10-SB filed by us with the Commission on August 27, 2001). |
|
|
4.1.1 |
Certificate of Amendment to Certificate of Incorporation, filed May 19, 2003 (Incorporated by reference to Exhibit 4.1.1 to the Registration Statement on Form S-3 (file no. 333-133331) filed by us with the Commission on April 17, 2006). |
|
|
4.1.2 |
Specimen Stock Certificate for Common Stock (filed herewith). |
|
|
4.2 |
Bylaws (Incorporated by reference to Exhibit 3(ii) to the Registration Statement on Form 10-SB filed by us with the Commission on August 27, 2001). |
|
|
4.3* |
Form of Stock Certificate for Preferred Stock. |
|
|
4.4* |
Form of Indenture, including form of Note. |
|
|
4.5* |
Form of Warrant Agreement, including form of Warrant. |
|
|
4.6* |
Form of Rights Certificate. |
|
|
4.7* |
Form of Pledge Agreement. |
|
|
4.8* |
Form of Unit Agreement. |
|
|
5.1 |
Opinion of Winston & Strawn LLP (filed herewith). |
|
|
12.1 |
Computation of Ratio of Earnings to Fixed Charges (filed herewith). |
|
|
23.1 |
Consent of Independent Registered Public Accounting Firm (filed herewith). |
|
|
23.2 |
Consent of Winston & Strawn LLP (included in Exhibit 5.1). |
|
|
24.1 |
Power of Attorney (included on Signature Page). |
|
|
25.1** |
Form T-1, Statement of Eligibility and Qualification under the Trust Indenture Act of 1939 of the Trustee under any indenture constituting Exhibit 4.4 hereto. |
| * | To be filed, if applicable, by amendment or as an exhibit to a document to be incorporated by reference
herein in connection with an offering of securities. |
| ** | To be filed separately under the electronic form type
305B2, if applicable. |
Exhibit 4.1.2
Specimen Stock Certificate for Common Stock
Exhibit 5.1
April 17, 2015
China Automotive Systems, Inc.
No. 1 Henglong Road, Yu Qiao Development Zone
Shashi District, Jing Zhou City
Hubei Province
People’s Republic of China
| Re: | China Automotive Systems, Inc. Registration Statement on Form S-3 for Primary Sale of Shares
of Common Stock by the Company and Resale of Shares of Common Stock by the Selling Shareholders with an aggregate public offering
price of up to US$200,000,000 |
Ladies and Gentlemen:
We have acted as special counsel to China
Automotive Systems, Inc., a Delaware corporation (the “Company”), in connection with the registration statement
on Form S-3 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Act”),
filed by the Company with the Securities and Exchange Commission (the “Commission”), relating to the proposed
offer, issuance and sale from time to time on a delayed or continuous basis pursuant to Rule 415 under the Act, as set forth in
the Registration Statement, the prospectus contained therein and any supplement to the prospectus, of the following securities
of the Company, as applicable:
| (i) | shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”); |
| (ii) | shares of preferred stock of the Company, par value $0.0001 per share (the “Preferred
Stock”); |
| (iii) | debt securities, in one or more series (the “Debt Securities”), which will be
issued under a form of Indenture filed as an exhibit to the Registration Statement (as amended or supplemented, the “Indenture”)
to be entered into by and among the Company and a trustee (the “Trustee”); |
| (iv) | warrants to purchase the Common Stock, the Preferred Stock and the Debt Securities (the “Warrants”); |
| (v) | rights to purchase the Common Stock, the Preferred Stock, the Debt Securities or other securities
(the “Rights”); and |
| (vi) | units in one more series, consisting of Common Stock, Preferred Stock, Debt Securities, Warrants
and/or Rights, in any combination (the “Units” and together with the Common Stock, the Preferred Stock, the
Debt Securities, the Warrants and the Rights, the “Securities”). |
The aggregate initial offering price of
the Securities sold under this prospectus will not exceed $150,000,000 (the “Company Offering”). In addition,
the selling shareholders are offering shares of common stock for resale having an aggregate offering price not to exceed $50,000,000
(the “Selling Shareholder Shares”), as set forth in the Registration Statement.
It is understood that the opinions set
forth below are to be used only in connection with the offer, issuance and sale of the Securities and the Selling Shareholder Shares
while the Registration Statement is in effect. The Registration Statement further provides that the Securities may be offered in
amounts, at prices and on terms to be set forth in one or more prospectus supplements.
This opinion letter is being delivered
in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Act.
In rendering the opinions set forth below,
we have examined and are familiar with originals or copies, certified or otherwise identified to our satisfaction, of (i) the certificate
of incorporation of the Company, as amended and in effect on the date hereof (“Certificate of Incorporation”),
(ii) the bylaws of the Company, as in effect on the date hereof (the “Bylaws” and together with the Certificate
of Incorporation, the “Organizational Documents”), (iii) the Registration Statement and (iv) resolutions of
the Board of Directors of the Company (the “Board”) relating to, among other matters, the filing of the Registration
Statement. We are familiar with the various corporate proceedings heretofore taken and additional proceedings proposed to be taken
by the Company in connection with the authorization, registration, issuance and sale of the Shares. We have also examined originals,
or copies certified to our satisfaction, of such corporate records of the Company and other instruments, certificates of public
officials and representatives of the Company and other documents as we have deemed necessary as a basis for the opinions hereinafter
expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted
to us as originals and the conformity with the originals of all documents submitted to us as copies. We also have assumed that
the Company will remain validly existing and in good standing under the laws of the state of Delaware. As to certain facts material
to this opinion letter, we have relied without independent verification upon oral and written statements and representations of
officers and other representatives of the Company.
On the basis of the foregoing, and subject
to (i) the Registration Statement and any amendments thereto being effective under the Act, (ii) the applicable Indenture under
which Debt Securities are issued having been validly executed and delivered by the Company and the other parties thereto, (iii)
a prospectus supplement having been filed with the Commission describing the Securities being offered thereby, (iv) all Securities
being issued and sold in the manner stated in the Registration Statement and the applicable prospectus supplement and in accordance
with a duly executed and delivered purchase, underwriting or similar agreement with respect to the Securities and (v) all Selling
Shareholder Shares being issued and sold in the manner stated in the Registration Statement and any applicable prospectus supplement
and in accordance with a duly executed and delivered purchase, underwriting or similar agreement with respect to the Shares, we
are of the opinion that:
| 1. | With respect to the Common Stock, when (i) the Board has taken all corporate action necessary to
approve the final terms of the issuance and sale of the Common Stock and (ii) the Company has received
the consideration therefor (and such consideration per share is not less than the par value per share of the Common Stock),
the Common Stock will be validly issued, fully paid and non-assessable. |
| 2. | With respect any series of Preferred Stock, when (i) the Board has taken all corporate action necessary
to approve the final terms of the issuance and sale of such Preferred Stock, (ii) the terms of the series of the Preferred Stock
have been duly established in conformity with the Organizational Documents and (iii) the Company has received the consideration
therefor, the Preferred Stock will be validly issued, fully paid and non-assessable. |
| 3. | With respect to the Debt Securities, when (i) the Board has taken all necessary corporate action
to approve the final terms of the issuance and sale of the Debt Securities, (ii) the applicable Indenture has been duly authorized,
executed and delivered, (iii) the terms of the Debt Securities have been duly established in conformity with the applicable Indenture
and do not violate any applicable law or result in a default under, or breach of, an agreement or instrument binding upon the Company
and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company,
(iv) such Debt Securities have been duly executed and delivered by the Company and the Debt Securities have been authenticated
by the Trustee in accordance with the applicable Indenture and (v) the Company has received the consideration therefor, such Debt
Securities will constitute valid and legally binding obligations of the Company enforceable in accordance with their terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to
or affecting creditors’ rights and to general equity principles. |
| 4. | With respect to the Warrants, when (i) the Board has taken all necessary corporate action to approve
the final terms of the issuance and sale of the Warrants, (ii) the applicable warrant agreement relating to the Warrants has been
duly authorized, executed and delivered, (iii) the Warrants are executed, countersigned and delivered in accordance with the applicable
warrant agreement against payment therefor and (iv) the Company has received the consideration therefor, the Warrants will constitute
valid and legally binding obligations of the Company enforceable in accordance with their terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’
rights and to general equity principles. |
| 5. | With respect to the Rights, when (i) the Board has taken all necessary corporate action to approve
the final terms of the issuance and sale of the Rights, (ii) the rights agreement relating to the Rights has been duly authorized,
executed and delivered, (iii) the certificates representing the Rights have been executed, countersigned and delivered in accordance
with the applicable rights agreement against payment therefor and (iv) the Company has received the consideration therefor, the
Rights will constitute valid and legally binding obligations of the Company enforceable in accordance with their terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to
or affecting creditors’ rights and to general equity principles. |
| 6. | With respect to the Units, when (i) the Board has taken all necessary corporate action to approve
the final terms of the issuance and sale of the Units, (ii) the purchase agreement relating to the Stock Purchase Units has been
duly authorized, executed and delivered, (iii) the Units have been executed, countersigned and delivered in accordance with the
applicable purchase agreement against payment therefor and (iv) the Company has received the consideration therefor, the Units
will constitute valid and legally binding obligations of the Company enforceable in accordance with their terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting
creditors’ rights and to general equity principles. |
| 7. | With respect to the Selling Shareholder Shares, the Selling Shareholder Shares have been duly authorized
and are validly issued, fully paid and non-assessable. |
The opinions expressed herein are based
upon and limited to the General Corporation Law of the State of Delaware (including the statutory provisions, all applicable provisions
of the Delaware Constitution and reported judicial decisions interpreting the foregoing). We express no opinion herein as to any
other laws, statutes, regulations or ordinances.
We hereby consent to the filing of this
opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to our firm under the caption “Legal Matters”
in the prospectus included in the Registration Statement. In giving such consent, we do not thereby admit that we are experts within
the meaning of the Act or that our firm is within the category of persons whose consent is required under Section 7 of the
Act or the rules and regulations of the Commission.
|
Very truly yours, |
|
|
|
|
|
/s/ Winston & Strawn LLP |
Exhibit 12.1
China Automotive
Systems, Inc.
Computation
of Ratio of Earnings to Fixed Charges
(Dollars in
thousands)
| |
Fiscal Year Ended December 31, | |
| |
2014 | | |
2013 | | |
2012 | | |
2011 | | |
2010 | |
Earnings: | |
| | | |
| | | |
| | | |
| | | |
| | |
Income before income taxes and equity in earnings of affiliated companies | |
$ | 46,081 | | |
$ | 38,241 | | |
$ | 30,069 | | |
$ | 52,099 | | |
$ | 71,416 | |
Add (deduct): | |
| | | |
| | | |
| | | |
| | | |
| | |
Fixed charges | |
| 2,549 | | |
| 2,298 | | |
| 3,464 | | |
| 5,393 | | |
| 3,970 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Earnings available for fixed charges (a) | |
$ | 48,630 | | |
$ | 40,539 | | |
$ | 33,533 | | |
$ | 57,492 | | |
$ | 75,386 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Fixed charges: | |
| | | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
$ | 1,816 | | |
$ | 1,652 | | |
$ | 3,144 | | |
$ | 4,967 | | |
$ | 3,605 | |
One-third of rental expense (1) | |
| 733 | | |
| 646 | | |
| 320 | | |
| 426 | | |
| 365 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Total fixed charges (b) | |
$ | 2,549 | | |
$ | 2,298 | | |
$ | 3,464 | | |
$ | 5,393 | | |
$ | 3,970 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Ratio of earnings to fixed charges (a/b) | |
| 19.08x | | |
| 17.64x | | |
| 9.68x | | |
| 10.66x | | |
| 18.99x | |
(1) |
Considered to be representative of interest factor in rent expense. |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
We hereby consent to the incorporation
by reference in this Registration Statement on Form S-3 of our report dated March 26, 2015, relating to the consolidated financial
statements and the effectiveness of internal control over financial reporting, which appears in China Automotive Systems, Inc.’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2014. We also consent to the reference to us under the heading
"Experts" in such Registration Statement.
/s/ PricewaterhouseCoopers Zhong Tian LLP |
|
PricewaterhouseCoopers Zhong Tian LLP |
|
Shanghai, People’s Republic of China |
|
April 17, 2015 |
|
China Automotive Systems (NASDAQ:CAAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
China Automotive Systems (NASDAQ:CAAS)
Historical Stock Chart
From Apr 2023 to Apr 2024